Landing Med, a Chinese medtech company focused on early cancer detection, has achieved a significant milestone by completing over 10 million cervical cancer screenings using artificial intelligence (AI). Established by Dr. Xiaorong Sun, the company has been integrating automation, digital, AI, and cloud computing technologies into Pap smear testing across China since 2017.
“I started Landing Med to address the challenge of a severe lack of pathologists and uneven distribution of health resources in China. As a female health tech entrepreneur, I strongly believe that women’s health is society’s health. We’re not just on a mission to save a woman’s life but to protect the well-being of her entire family,” says Dr. Xiaorong Sun, Founder and Chairwoman of Landing Med.
The Pap smear, a crucial preventive measure against cervical cancer, has faced global challenges due to the scarcity of pathologists, especially in low and middle-income nations. Conventional methods involving manual cell review under microscopes are labor-intensive and limit the productivity of cytopathologists. Landing Med’s AI-enhanced approach has revolutionized this process by significantly reducing the time required for review and increasing the scalability of Pap smear testing.
In Landing Med’s state-of-the-art system, AI technology plays a pivotal role by identifying suspicious cells, thus enabling pathologists to concentrate on making timely and accurate diagnoses. The effectiveness of this AI algorithm has been validated through multiple scientific journals, indicating comparable performance to human pathologists, but with increased sensitivity.
The Hubei Provincial Health Commission’s selection of Landing Med in 2022 to screen over 12 million women for cervical cancer underscores the company’s commitment to providing accessible health solutions, particularly in rural areas. Additionally, Landing Med has developed an online platform for remote cancer diagnosis in rural clinics.
Internationally, Landing Med has made strides by establishing AI-driven cervical cancer screening labs in Pakistan, Malaysia, and Indonesia, with plans to expand its reach. “Our results prove that AI technology can effectively enhance screening programs in countries with limited pathology resources,” says Dr. Sun. “Health equity is no longer a dream and we aim to provide more underserved communities around the world with accessible and affordable cancer detection solutions.”
